BACKGROUND: Transcatheter aortic valve implantation (TAVI) is the standard therapy for high-risk patients with aortic stenosis (AS). TAVI-outcomes are widely investigated in comparison to surgical aortic valve replacement (SAVR), but less is known about infectious complications after TAVI. We aimed to compare early and mid-term infectious outcomes of patients undergoing TAVI or SAVR. METHODS: The present study is a prospective single-centre study including 200 consecutive patients between 06/2014-03/2015 undergoing TAVI (either transfemoral or transapical and transaortic, n=47+53=100) or SAVR (either isolated or concomitant with CABG, n=52+48=100). The mean age and log. EuroSCORE were significantly different between both groups (81±6 versus 69±11 years, P<0.001 and 23.1%±13.8% versus 8.7%±9.5%, P<0.001). Primary endpoints included wound healing disorders, respiratory and urinary tract infections and incidence of endocarditis or sepsis within hospital stay. Secondary endpoints included infectious parameters, infectious related rehospitalisation and 2-year mortality. RESULTS: Primary endpoints showed no difference in overall TAVI- versus SAVR-groups regarding respiratory- (14% versus 19%, P=0.45), urinary-tract (7% versus 4%, P=0.54) infections, sepsis (5% versus 6%, P=1.0), endocarditis (0% versus 1%, P=1.0) or 30-day mortality (10% versus 4%, P=0.09), except for wound disorders, which were significantly lower in the TAVI-group (1% versus 8%, P=0.035), respectively. Secondary endpoints reported no difference regarding infectious related rehospitalisation (4% versus 4%, P=1.0), but significantly higher 2-year mortality (28% versus 16%, P=0.048) in the TAVI-group. CONCLUSIONS: So far, little has been studied about infectious complications after TAVI. This study reports no difference between the overall TAVI and SAVR groups regarding infectious complications. However, SAVR group show more wound healing disorders but less mortality than TAVI group.
BACKGROUND: Transcatheter aortic valve implantation (TAVI) is the standard therapy for high-risk patients with aortic stenosis (AS). TAVI-outcomes are widely investigated in comparison to surgical aortic valve replacement (SAVR), but less is known about infectious complications after TAVI. We aimed to compare early and mid-term infectious outcomes of patients undergoing TAVI or SAVR. METHODS: The present study is a prospective single-centre study including 200 consecutive patients between 06/2014-03/2015 undergoing TAVI (either transfemoral or transapical and transaortic, n=47+53=100) or SAVR (either isolated or concomitant with CABG, n=52+48=100). The mean age and log. EuroSCORE were significantly different between both groups (81±6 versus 69±11 years, P<0.001 and 23.1%±13.8% versus 8.7%±9.5%, P<0.001). Primary endpoints included wound healing disorders, respiratory and urinary tract infections and incidence of endocarditis or sepsis within hospital stay. Secondary endpoints included infectious parameters, infectious related rehospitalisation and 2-year mortality. RESULTS: Primary endpoints showed no difference in overall TAVI- versus SAVR-groups regarding respiratory- (14% versus 19%, P=0.45), urinary-tract (7% versus 4%, P=0.54) infections, sepsis (5% versus 6%, P=1.0), endocarditis (0% versus 1%, P=1.0) or 30-day mortality (10% versus 4%, P=0.09), except for wound disorders, which were significantly lower in the TAVI-group (1% versus 8%, P=0.035), respectively. Secondary endpoints reported no difference regarding infectious related rehospitalisation (4% versus 4%, P=1.0), but significantly higher 2-year mortality (28% versus 16%, P=0.048) in the TAVI-group. CONCLUSIONS: So far, little has been studied about infectious complications after TAVI. This study reports no difference between the overall TAVI and SAVR groups regarding infectious complications. However, SAVR group show more wound healing disorders but less mortality than TAVI group.
Authors: Robert O Bonow; Blase A Carabello; Kanu Chatterjee; Antonio C de Leon; David P Faxon; Michael D Freed; William H Gaasch; Bruce Whitney Lytle; Rick A Nishimura; Patrick T O'Gara; Robert A O'Rourke; Catherine M Otto; Pravin M Shah; Jack S Shanewise; Sidney C Smith; Alice K Jacobs; Cynthia D Adams; Jeffrey L Anderson; Elliott M Antman; Valentin Fuster; Jonathan L Halperin; Loren F Hiratzka; Sharon A Hunt; Bruce W Lytle; Rick Nishimura; Richard L Page; Barbara Riegel Journal: J Am Coll Cardiol Date: 2006-08-01 Impact factor: 24.094
Authors: Craig R Smith; Martin B Leon; Michael J Mack; D Craig Miller; Jeffrey W Moses; Lars G Svensson; E Murat Tuzcu; John G Webb; Gregory P Fontana; Raj R Makkar; Mathew Williams; Todd Dewey; Samir Kapadia; Vasilis Babaliaros; Vinod H Thourani; Paul Corso; Augusto D Pichard; Joseph E Bavaria; Howard C Herrmann; Jodi J Akin; William N Anderson; Duolao Wang; Stuart J Pocock Journal: N Engl J Med Date: 2011-06-05 Impact factor: 91.245
Authors: Alain Cribier; Helene Eltchaninoff; Assaf Bash; Nicolas Borenstein; Christophe Tron; Fabrice Bauer; Genevieve Derumeaux; Frederic Anselme; François Laborde; Martin B Leon Journal: Circulation Date: 2002-12-10 Impact factor: 29.690
Authors: Cosmo Godino; Francesco Maisano; Matteo Montorfano; Azeem Latib; Alaide Chieffo; Iassen Michev; Rasha Al-Lamee; Marta Bande; Marco Mussardo; Francesco Arioli; Alfonso Ielasi; Micaela Cioni; Maurizio Taramasso; Irina Arendar; Antonio Grimaldi; Pietro Spagnolo; Alberto Zangrillo; Giovanni La Canna; Ottavio Alfieri; Antonio Colombo Journal: JACC Cardiovasc Interv Date: 2010-11 Impact factor: 11.195
Authors: Josep Rodés-Cabau; John G Webb; Anson Cheung; Jian Ye; Eric Dumont; Christopher M Feindel; Mark Osten; Madhu K Natarajan; James L Velianou; Giuseppe Martucci; Benoît DeVarennes; Robert Chisholm; Mark D Peterson; Samuel V Lichtenstein; Fabian Nietlispach; Daniel Doyle; Robert DeLarochellière; Kevin Teoh; Victor Chu; Adrian Dancea; Kevin Lachapelle; Asim Cheema; David Latter; Eric Horlick Journal: J Am Coll Cardiol Date: 2010-01-22 Impact factor: 24.094
Authors: Gabriela Tirado-Conte; Afonso B Freitas-Ferraz; Luis Nombela-Franco; Pilar Jimenez-Quevedo; Corina Biagioni; Ana Cuadrado; Ivan Nuñez-Gil; Pablo Salinas; Nieves Gonzalo; Carlos Ferrera; David Vivas; Javier Higueras; Ana Viana-Tejedor; Maria Jose Perez-Vizcayno; Isidre Vilacosta; Javier Escaned; Antonio Fernandez-Ortiz; Carlos Macaya Journal: Am J Cardiol Date: 2016-05-14 Impact factor: 2.778
Authors: Sophia L Alexis; Aaqib H Malik; Isaac George; Rebecca T Hahn; Omar K Khalique; Karthik Seetharam; Deepak L Bhatt; Gilbert H L Tang Journal: J Am Heart Assoc Date: 2020-08-08 Impact factor: 5.501